News for CRISPR Therapeutics AG (CRSPN.MX)

Cathie Wood is bullish on biotech companies using gene sequencing, AI, and CRISPR tech to cure previously untreatable diseases.

On Tuesday, Cathie Wood-led Ark Invest executed notable trades involving NVIDIA Corp NVDA, Advanced Micro Devices Inc. AMD, and Tesla Inc. TSLA. These trades co...

On May 21, 2025, JMP Securities analyst Silvan Tuerkcan reiterated a "Market Outperform" rating for CRISPR Therapeutics (CRSP). The analyst maintained a price t

CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co-develop an siRNA drug targeting blood clotting disorders.

Summary On May 19, 2025, CRISPR Therapeutics AG (CRSP), a leader in gene-based medicines, announced a strategic partnership with Sirius Therapeutics to co-devel

-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small inter

Market Analysis by covering: Crispr Therapeutics AG. Read 's Market Analysis on Investing.com

CRISPR Therapeutics is at the forefront of personalized gene therapy innovations. Analysts provide a mixed forecast with significant potential upside.

On Wednesday, Cathie Wood-led Ark Invest executed significant trades, including a notable purchase of Airbnb Inc. (NASDAQ:ABNB), a sell-off of Palantir Technologies Inc. (NASDAQ:PLTR) ,

On Tuesday, Cathie Wood‘s Ark Invest made significant moves by selling shares of Palantir Technologies Inc. PLTR and Archer Aviation Inc. ACHR. These trades c...

Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

On May 9, 2025, Barclays analyst Gena Wang maintained the rating of CRISPR Therapeutics (CRSP) at "Equal-Weight." However, the firm has lowered its price target

Barclays has adjusted its price target for Crispr Therapeutics (CRSP), reducing it from $56 to $42 while maintaining an Equal Weight rating on the stock. This d

On Wednesday, May 7, 2025, Cathie Wood's Ark Invest Pours $24M Into Nvidia and AMD While Offloading $38.8M in Palantir Shares.

Crispr Therapeutics AG shows promise with innovative gene therapies like CTX-310, strong cash reserves, and a bullish long-term outlook. Click for my CRSP update.

CRISPR Therapeutics AG CRSP posted a loss for the first quarter on Tuesday. The company posted a quarterly loss of $1.58 per share, compared to market estimate...

On May 7, 2025, Chardan Capital analyst Geulah Livshits reaffirmed the "Buy" rating for CRISPR Therapeutics (CRSP), despite making a slight adjustment to the pr

An analyst at Clear Street, Bill Maughan, has raised his recommendation for Crispr Therapeutics (CRSP) from Hold to Buy, maintaining the price target at $45. Th

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.